Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar;15(3):148-160.
doi: 10.1038/s41582-018-0128-2.

Deep brain stimulation: current challenges and future directions

Affiliations
Review

Deep brain stimulation: current challenges and future directions

Andres M Lozano et al. Nat Rev Neurol. 2019 Mar.

Abstract

The clinical use of deep brain stimulation (DBS) is among the most important advances in the clinical neurosciences in the past two decades. As a surgical tool, DBS can directly measure pathological brain activity and can deliver adjustable stimulation for therapeutic effect in neurological and psychiatric disorders correlated with dysfunctional circuitry. The development of DBS has opened new opportunities to access and interrogate malfunctioning brain circuits and to test the therapeutic potential of regulating the output of these circuits in a broad range of disorders. Despite the success and rapid adoption of DBS, crucial questions remain, including which brain areas should be targeted and in which patients. This Review considers how DBS has facilitated advances in our understanding of how circuit malfunction can lead to brain disorders and outlines the key unmet challenges and future directions in the DBS field. Determining the next steps in DBS science will help to define the future role of this technology in the development of novel therapeutics for the most challenging disorders affecting the human brain.

PubMed Disclaimer

Conflict of interest statement

Competing interests

A.M.L. is a consultant to Medtronic, Abbott (formerly St. Jude) and Boston Scientific and is Scientific Director of Functional Neuromodulation. H.B. has received honoraria for speaking from AlphaOmega, Medtronic and Boston Scientific and research support from the Magnet Program of the Israel Ministry of Economics. P.B. has received honoraria for speaking from Medtronic and Boston Scientific. S.C. is a consultant for Boston Scientific and for Medtronic and has received financial support from Medtronic for preclinical research purposes in the field of deep brain stimulation (DBS). K.M. has chaired advisory boards for studies of DBS for obsessive–compulsive disorder sponsored by Medtronic and has received travel and accommodation support to attend meetings from Medtronic and Abbott. C.C.M. is a paid consultant for Boston Scientific Neuromodulation and Kernel as well as a shareholder in the following companies: Surgical Information Sciences, Inc.; Autonomic Technologies, Inc.; Cardionomic, Inc.; Enspire DBS, Inc.; and Neuros Medical, Inc. T.S. has received limited research support for three investigator-initiated studies from Medtronic. M.S. owns stock in General Electric. J.V. receives grants and personal fees from Boston Scientific and is a consultant and paid speaker for Medtronic. J.K.K. is a consultant to Medtronic and Boston Scientific; has received fees for speaking from Abbott; is a past and honorary president of the European Society for Stereotactic and Functional Neurosurgery; and is a past president of the World Society for Stereotactic and Functional Neurosurgery. The other authors have no competing interests.

Figures

Fig. 1
Fig. 1. Deep brain stimulation mechanisms.
a | Neurotransmitters (inset) are released in response to stimulation, leading to calcium waves and subsequent release of gliotransmitters. This release influences synaptic plasticity, leading to arteriole dilation and increased regional blood flow. b | Deep brain stimulation (DBS)-induced changes in local field potentials within the subthalamic nucleus. Activity in the beta band is rapidly reduced with DBS at 3 V and then resumes with stimulation off.

References

    1. Lozano AM, Lipsman N. Probing and regulating dysfunctional circuits using deep brain stimulation. Neuron. 2013;77:406–424. - PubMed
    1. Kuhn AA, et al. High-frequency stimulation of the subthalamic nucleus suppresses oscillatory beta activity in patients with Parkinson’s disease in parallel with improvement in motor performance. J Neurosci. 2008;28:6165–6173. - PMC - PubMed
    1. Lipsman N, et al. Subcallosal cingulate deep brain stimulation for treatment-refractory anorexia nervosa: a phase 1 pilot trial. Lancet. 2013;381:1361–1370. - PubMed
    1. Laxton AW, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. Ann Neurol. 2010;68:521–534. - PubMed
    1. Ballanger B, et al. Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson’s disease: a [(15)O] H2O PET study. Hum Brain Mapp. 2009;30:3901–3909. - PMC - PubMed

Publication types